Roche finally drops curtain on AKT drug ipatasertib

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update

Ratio raises $20m to build on its radiopharma ambitions

Boston-based biotech Ratio Therapeutics has doubled its funding at a stroke with a $20 million Series A that will be used to usher its targeted radiotherapies into clinica

Supercharge Targeting FcRn & FcγR Pathways via Fc Optimi...

Trial sets up earlier use of J&J's Carvykti in myeloma

One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti.

Could your loyalty card help spot cancer? Study says yes

A study by UK researchers has found that buying patterns for over-the-counter (OTC) medicines for pain and indigestion, recorded using a store loyalty card, could be used to pick up early s